Deucravacitinib in dermatology: current indication and existing off-label data

Tyrosine kinase 2 (TYK2) inhibition has recently emerged as a novel therapeutic strategy in dermatology, targeting key cytokine pathways involved in immune-mediated inflammatory diseases. Deucravacitinib, an oral, selective TYK2 inhibitor that binds the regulatory pseudokinase domain, modulates sign...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Michela D’Agostino, Luca Potestio, Nello Tommasino, Matteo Megna
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	BioExcel Publishing Ltd 2026-06-01
Edice:	Drugs in Context
Témata:	dermatology deucravacitinib immunemediated inflammatory diseases psoriasis real-world evidence tyk2 inhibition
On-line přístup:	https://www.drugsincontext.com/deucravacitinib-in-dermatology-current-indication-and-existing-off-label-data/
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!